Company Overview and Pipeline Outlook
Bristol Myers Squibb (NYSE: BMY) is a global pharmaceutical leader known for its oncology and cardiovascular therapies. The company is at a pivotal juncture as it works to replenish aging drug franchises with new innovations. While BMS itself hasn’t yet led a recent breakthrough in breast cancer, the oncology landscape is rapidly advancing – for instance, Gilead’s Trodelvy (an antibody-drug conjugate) combined with Merck’s Keytruda immunotherapy has significantly improved outcomes in aggressive triple-negative breast cancer ([1]). BMS is striving to participate in the next wave of such breakthroughs through hefty R&D investments and strategic alliances. In June 2025, BMS committed up to $11.1 billion in a partnership with BioNTech to co-develop BNT327 (pumitamig), a next-generation immunotherapy aimed at boosting immune response and cutting off tumors’ blood supply ([2]). This experimental drug – initially targeted at lung cancer – showed 76% tumor shrinkage in a Phase II trial ([2]) and could be a platform for treating other hard-to-treat tumors. BMS’s willingness to pay $1.5 billion upfront for this collaboration underscores its determination to stay at the forefront of oncology innovation ([2]). These pipeline moves offer hope that BMS can eventually bring forward breakthrough therapies that benefit patients with challenging cancers (including breast cancer) in the future.
Bryce Paul's #1 Crypto To Buy — October 2025
To offset looming patent expirations, BMS has introduced a suite of new products and is seeing early traction. Its “growth portfolio” – recent launches and non-legacy drugs – is expanding rapidly. In Q3 2025, sales of newer therapies (including a new subcutaneous version of Opdivo immunotherapy and the heart drug Camzyos) rose 18% year-over-year to $6.9 billion, helping to counterbalance declines in older products ([3]). Key growth contributors include Opdualag (a novel melanoma immunotherapy combo), Camzyos (for hypertrophic cardiomyopathy), Sotyktu (a TYK2 inhibitor for psoriasis), Reblozyl (for anemia), and cell therapies Breyanzi/Abecma for blood cancers. BMS has even diversified beyond oncology with the $14 billion acquisition of Karuna Therapeutics, gaining the novel schizophrenia drug Cobenfy (KarXT) ([4]). These investments reflect management’s strategy to “minimize the decline period and accelerate future growth,” even as older revenues erode ([5]). The critical question is whether this new wave of drugs can fully bridge the gap left by blockbuster products that are now past their prime.
Dividend Policy, History & Yield
BMS is distinguished by a shareholder-friendly dividend policy. The company recently declared its 16th consecutive annual dividend increase, raising the quarterly payout by ~3.3% to $0.62 per share ([6]). This brings the indicated annualized dividend to $2.48 per share for 2025 ([6]), extending a long track record of consistent hikes. Even as drug development requires heavy investment, BMS has prioritized steady returns to shareholders. The dividend has grown modestly but reliably each year, signaling management’s confidence in cash flow stability. In 2023, BMS paid out $4.7 billion in dividends ([7]), covered by operational cash flows and supplemented by proceeds from asset sales and debt issuance as needed. (As a pharma company, BMS reports standard earnings and free cash flow rather than REIT-style FFO/AFFO metrics, which are not applicable here.)
At recent share prices, BMY’s dividend yield hovers around the mid-single-digits (approximately 4–5%). This yield is notably higher than most Big Pharma peers – for example, Eli Lilly’s yield is under 1% after its latest increase ([8]). BMS’s elevated yield partly reflects its depressed stock price and investor caution about upcoming challenges. For income investors, however, the stock offers an attractive payout backed by a large-cap pharma’s cash generation. BMS’s dividend coverage appears solid for now, with the payout constituting a reasonable share of free cash flow (the company also executed about $5.2 billion in share buybacks in 2023 ([7]), indicating additional cash return capacity). Management has emphasized commitment to the dividend, and given BMS’s 93-year history of uninterrupted dividends, the expectation is for continued, incremental raises barring any severe downturn. One caveat: as we discuss under Risks, BMS is entering a period of earnings pressure, so future dividend growth may remain in the low-single-digit range until new drugs scale up.
Leverage, Debt Maturities & Coverage
BMS’s leverage has climbed significantly in recent years, chiefly due to its aggressive acquisitions and shareholder returns. As of year-end 2024, the company carried $49.6 billion in total debt (short and long-term combined) ([9]), up from about $39.8 billion a year prior. In fact, long-term borrowings jumped nearly 50% year-over-year to over $50 billion by late 2024, pushing BMS’s debt-to-equity ratio to approximately 2.9 – an unusually high level for a pharma company ([8]). This leverage increase was partly driven by the $14 billion Karuna acquisition and other business development deals, as well as funding hefty share buybacks ([10]) ([7]). While BMS remains investment-grade, its debt load is now an important watch item for investors.
Start collecting royalty checks before the first national payout.
Step 1
Learn the exact royalty play paying monthly checks
Step 2
Start with as little as $50 — get paid next month
Step 3
Position yourself before Wall Street moves in
On a positive note, the debt maturity profile is well-staggered and manageable in the near term. Upcoming maturities are spread roughly as follows: $2.9 billion due in 2024, $1.9 billion in 2025, $2.0 billion in 2026, $2.0 billion in 2027, and $1.5 billion in 2028 ([7]). No single year beyond 2024 has an outsized repayment burden, which gives BMS flexibility to refinance or repay gradually. The company has been opportunistic in issuing debt (e.g. taking advantage of low rates in prior years) and also redeemed some high-coupon Celgene debt in 2022. Interest coverage remains comfortable – interest payments are roughly $1.3–1.4 billion per year over the next five years ([7]), while BMS’s EBITDA and operating cash flow are many times that figure. By way of illustration, interest expense consumed about $1.2 billion in 2023 ([7]), against over $10 billion in adjusted operating earnings (excluding large one-time charges). This implies an interest coverage ratio on the order of 7–8×, indicating BMS can easily meet its debt service obligations for now.
That said, leverage metrics have deteriorated. Net debt (debt minus cash) rose to $38.5 billion at 2024’s end from $27.1 billion a year prior ([9]). The company “loaded up on debt to boost operations,” as one analyst noted, and its debt load is high both in absolute terms and relative to equity capital ([8]). Management is aware of this and has expanded cost-cutting plans (recently adding $2 billion more in savings initiatives through 2027) ([5]). BMS’s strong cash flows historically allowed it to de-leverage after big deals (for example, it paid down significant debt after the 2019 Celgene merger), but the new borrowing for Karuna and pipeline deals will likely slow the pace of improvement. Credit rating agencies have BMS in the single-A category; they will be focusing on how quickly the company can stabilize earnings and reduce debt in the back half of the decade. Overall, BMS’s liquidity is ample (over $11 billion in cash on hand ([9])) and near-term refinancing risk is low – but the balance sheet flexibility to do additional mega-deals may be constrained until some debt is whittled down.
Valuation and Comparative Metrics
BMY shares currently trade at a depressed valuation relative to both the market and pharma peers. Healthcare stocks broadly have lagged in 2025, and investors have assigned BMS a notably low earnings multiple. The stock’s forward P/E ratio is in the high single digits, well below the S&P 500’s ~22× and even below the healthcare sector average of ~16× ([11]). In fact, BMS and Merck are trading far under their historical P/E averages, attracting interest from value-oriented investors ([11]). This discount reflects the market’s concern over BMS’s patent cliff and uncertain growth trajectory in the near term. By comparison, Big Pharma rivals with clearer growth drivers trade higher – for example, Merck is around 13–14× forward earnings and Johnson & Johnson about 15×, while high-growth Eli Lilly commands a much richer multiple (30×+). BMS’s EV/EBITDA is likewise modest (roughly 9–10× on 2024 numbers, vs. low-teens for peers).
On a dividend yield basis, BMY also screens as undervalued. Its ~4–5% yield is roughly 1.5–2× the pharma industry median, indicating the stock’s price weakness. Typically, such a yield in Big Pharma can signal either an exceptional buying opportunity or underlying challenges. In BMS’s case, it’s a bit of both. Much of the “bad news” may already be priced in ([11]) – investors know that Revlimid and other legacy drugs are declining, and BMS’s valuation now assumes a revenue dip and rebuilding period. Bulls argue that if BMS’s new product portfolio even partially succeeds, the stock is a bargain at these levels. They point to the company’s diversified pipeline and track record of eventually overcoming past patent cliffs (e.g., after Plavix lost exclusivity years ago, BMS rebounded with Eliquis and Opdivo). Bears, however, worry that BMS could be a “value trap,” with earnings continuing to slide as more drugs face competition. For now, the low multiple and high yield provide a margin of safety, but a re-rating of the stock likely depends on clear signs that BMS can return to growth in the second half of the decade.
In terms of peer comparisons, BMS’s metrics highlight the divide between it and more growth-oriented pharma companies. Eli Lilly (LLY), buoyed by its obesity and diabetes franchises, trades at a tiny 0.8% yield and a premium valuation ([8]). Merck (MRK), facing its own 2028 Keytruda patent cliff, yields ~3% and trades at a middling multiple. Pfizer (PFE), which is navigating a post-Covid revenue drop, has a high yield (~5%) but also a cautious outlook. BMS sits somewhere in between – larger than Pfizer in oncology exposure, but lacking a singular growth driver like Lilly’s Mounjaro. Its sum-of-the-parts valuation (with a profitable core, a deep pipeline, and significant cash flows) suggests upside if management can execute on pipeline delivery. Thus, BMY appears undervalued relative to its normalized earnings power, but the timeline for unlocking that value is uncertain. Investors are essentially paying a low price now for potential long-term gains, and getting paid a solid dividend while they wait.
Risks, Red Flags, and Remaining Questions
Despite its strengths, BMS faces significant risks that investors should weigh:
– Patent Expirations & Revenue Cliff: BMS is now in the throes of a major patent cliff. The company projects a sharper-than-expected drop in 2025 revenue to ~$45.5 billion (–6% year-on-year) ([5]) as multiple oncology blockbusters succumb to generic competition. Key Celgene-origin drugs – Revlimid, Pomalyst, Sprycel, and Abraxane – are already seeing steep declines ([5]). In Q3 2025, Revlimid sales plunged 59% to $575 million ([3]), a harbinger of what full generic erosion looks like. By 2026–27, these losses will deepen. Perhaps even more concerning, BMS’s top-selling Eliquis (a blood thinner co-marketed with Pfizer) faces U.S. patent expiry by 2028. Eliquis contributes roughly $10 billion+ annually, so its anticipated loss will create another earnings hole. BMS is racing against time to ramp up new product sales before these high-margin older drugs fade out. Failure to replace the revenue could compress cash flows and pressure the dividend in out-years. This transition period is a core reason behind BMY’s low valuation. The company has expanded a cost-cutting program by $2 billion (to $3.5 billion total) through 2027 to help mitigate the impact ([5]). Still, there’s execution risk in achieving those savings without hindering innovation.
– Pipeline Dependence & R&D Risk: BMS’s future hinges on the success of its pipeline and recent launches – many of which address highly competitive fields. For instance, in immuno-oncology, Merck’s Keytruda dominates, and dozens of companies are developing novel cancer agents. BMS’s big bet on BioNTech’s pumitamig (BNT327) will require navigating complex trials and regulatory hurdles to prove it can rival Keytruda ([2]). In hematology, BMS’s cell therapies (Breyanzi, Abecma) and anemia drug Reblozyl face emerging competition and adoption challenges. The company’s diversification into cardiovascular (Camzyos) and immunology (Sotyktu) also pits it against entrenched rivals (e.g., Camzyos competes with older heart drugs; Sotyktu competes with biologics in psoriasis). Clinical setbacks remain a constant risk – illustrated recently when BMS’s newly acquired schizophrenia drug Cobenfy failed a key adjunct therapy trial, undermining hopes for that expansion and causing a 5% stock drop ([10]). Notably, analysts had viewed Cobenfy (KarXT) as a “key growth driver” following the pricey Karuna acquisition ([10]). Such disappointments raise red flags about BMS’s business development decisions and the ROI on its $14 billion spend. If too many pipeline assets falter (or launch slower than expected), BMS could find itself with a gap in its growth story just as legacy drugs wane.
– Leverage and Financial Flexibility: As discussed, BMS’s debt load is high after recent deals. While current interest coverage is solid, rising interest rates mean refinancing debt could become more expensive over time. A highly leveraged balance sheet also leaves less room for error – if cash flows dip due to patent losses or if any big litigation hit occurs, BMS might have to prioritize debt servicing over share buybacks or even limit dividend growth. The company’s debt/EBITDA spike to ~3× (post-Karuna) is something rating agencies will monitor. So far, BMS has maintained a strong credit profile, but further leveraging (e.g., another large acquisition) could jeopardize that. Investors should watch for management’s commentary on capital allocation: will they commit to de-leveraging in 2025–2026, or continue with aggressive M&A? Any large new acquisitions could strain the balance sheet and potentially dilute shareholder value if paid with equity.
– Legal and Regulatory Overhang: BMS is contending with a few notable legal issues. It is currently facing a $6.7 billion lawsuit related to allegations that the company deliberately delayed FDA approval of certain Celgene drugs to avoid payout under contingent value rights ([12]). A U.S. judge recently allowed key parts of this case to proceed ([12]). While the outcome is uncertain (and BMS vehemently denies wrongdoing), an adverse judgment or settlement could be costly. Separately, the entire pharma sector is under regulatory pressure on drug pricing. U.S. policy changes – from Medicare price negotiation to efforts tying drug prices to inflation – pose a long-term risk to profit margins. In 2025, the healthcare sector’s underperformance has been partly attributed to these policy headwinds ([11]). BMS, with lucrative drugs like Eliquis and Opdivo, will likely see some of its products subject to government price negotiations by late this decade. There’s also political scrutiny on oncology drug pricing and PBM (pharmacy benefit manager) dynamics that could affect Eliquis’s future sales. More broadly, global pricing pressures (as governments worldwide seek to contain healthcare costs) could slow BMS’s revenue growth or force deeper discounts. Investors should be aware that regulatory risk is high and largely beyond the company’s control.
– Macroeconomic and Other Risks: As a global company, BMS is exposed to currency fluctuations (a strong dollar can hit overseas revenue) and economic conditions that affect healthcare spending. Supply chain issues or manufacturing problems (for complex biologics or cell therapies) could also impact product availability. Additionally, the company is in the midst of a CEO transition – longtime CEO Giovanni Caforio handed the reins to Chris Boerner (former CCO) in 2023. A new chief executive often brings strategic shifts; so far Boerner has doubled down on pipeline replenishment via deals ([3]). Investors will be watching how the new leadership executes strategy and allocates capital. Any sign of integration hiccups from acquisitions or a strategic misstep could be a red flag.
Conclusion and Open Questions
Bristol Myers Squibb finds itself in a challenging yet potentially rewarding phase. The optimistic scenario is that BMS’s slate of new drugs and alliances will reignite growth by the late 2020s. The company’s recent performance offers glimmers of hope: core franchises like Opdivo and Eliquis are still growing strongly in the interim ([3]), and new products are steadily gaining traction (BMS’s newer drugs contributed nearly $6.4 billion in Q4 2024 revenue, up 21% year-on-year ([9])). BMS’s ability to consistently beat earnings forecasts in 2024 and raise its sales guidance ([3]) shows that it can navigate near-term headwinds. Furthermore, advances in cancer treatment – including those by competitors – validate the investment in innovation. The proliferation of effective therapies for breast cancer and other tough diseases is encouraging for patients and places pressure on BMS (and peers) to deliver the next breakthrough. With its deep expertise in immunotherapy and recent cash infusion into R&D, BMS could very well be a contributor to the “hope” for patients in the form of new treatments down the line.
However, the pessimistic scenario cannot be ignored. BMS must execute almost flawlessly: launching products, hitting trial endpoints, and possibly making additional tuck-in acquisitions – all while trimming costs and managing a hefty debt load. Open questions include: Will the promising pipeline compounds meet clinical expectations, or will some falter as KarXT did? Can BMS replace the Eliquis revenue by 2028, given the relatively short runway? Is the company prepared to handle a scenario where multiple new launches underperform, or will it face a gap that necessitates deeper restructuring? Additionally, how will management balance the need for further M&A to bolster the pipeline against the reality of increased leverage and investor pushback on big deals? The outcome of the CVR lawsuit and evolving drug pricing rules also hang in the air – either could impact BMS’s finances by billions of dollars or alter how it prices future drugs.
From an investment standpoint, BMY offers a tantalizing mix of high current income and turnaround potential, albeit with above-average risk for a large pharma. The dividend is well-supported in the near term, providing investors some return as they wait for clarity on the pipeline’s success. BMS’s valuation suggests a margin of safety, but realizing upside will require concrete signs that new growth drivers can stabilize revenues by 2025–2026. In the next 12–18 months, watch for pivotal Phase III trial readouts (in oncology and immunology), initial sales trends for recent launches (e.g., Camzyos, Opdualag, Sotyktu), and any bold moves by management (such as partnerships or spinoffs). Each of these will inform whether BMS is on track to overcome its patent cliff trough.
In summary, Bristol Myers Squibb is navigating a period of significant transition. A breakthrough drug that offers hope for patients – much like the advances we’re seeing in breast cancer by others – could be on BMS’s horizon if its pipeline delivers. The company’s story in the coming years will center on its ability to innovate out of the shadow of lost exclusivity. For now, BMY remains a show-me stock: it has laid the groundwork with strategic deals and new launches, but investors need evidence of durable growth emerging from these investments. The pieces are in place, and the next few years will determine if Bristol Myers Squibb can write its own comeback script and, in doing so, bring transformational new therapies to patients who urgently need them.
Sources:
– Bristol Myers Squibb investor press release on dividend increase ([6]). – Motley Fool analysis of BMS’s dividend hike and debt levels ([8]) ([8]). – SEC 10-K filings for 2023/2024 (debt and interest obligations) ([9]) ([7]). – Reuters – Struggling US healthcare stocks (sector valuation context) ([11]) ([11]). – Reuters – Q4 2024 earnings and 2025 forecast (patent cliff impact) ([5]). – Reuters – Q3 2025 sales beat (new product growth vs. Revlimid decline) ([3]). – Reuters – BioNTech partnership and trial results (BNT327 immunotherapy deal) ([2]). – Reuters – Karuna/Cobenfy trial failure (pipeline risk) ([10]) ([10]). – Reuters – CVR lawsuit ruling (legal risk) ([12]). – Reuters – Trodelvy breast cancer trial (industry breakthrough example) ([1]).
Sources
- https://reuters.com/business/healthcare-pharmaceuticals/gileads-trodelvy-cuts-breast-cancer-risk-by-38-trial-2025-10-19/
- https://reuters.com/business/healthcare-pharmaceuticals/biontech-bristol-myers-immunotherapy-shows-encouraging-tumour-shrinkage-phase-ii-2025-09-08/
- https://reuters.com/business/healthcare-pharmaceuticals/bristol-myers-beats-quarterly-revenue-estimates-strong-opdivo-sales-2025-10-30/
- https://reuters.com/business/healthcare-pharmaceuticals/bristol-myers-plans-launch-schizophrenia-drug-uk-list-price-equal-us-2025-09-22/
- https://reuters.com/business/healthcare-pharmaceuticals/bristol-sees-sharper-2025-revenue-drop-after-better-than-forecast-q4-2025-02-06/
- https://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Announces-Dividend-Increase/default.aspx
- https://sec.gov/Archives/edgar/data/14272/000001427224000044/bmy-20231231.htm
- https://fool.com/investing/2024/12/19/these-2-stocks-just-declared-dividend-raises-that/
- https://news.bms.com/news/corporate-financial/2025/Bristol-Myers-Squibb-Reports-Fourth-Quarter-and-Full-Year-Financial-Results-for-2024/default.aspx
- https://reuters.com/business/healthcare-pharmaceuticals/bristol-myers-cobenfy-fails-meet-main-goal-add-on-treatment-schizophrenia-2025-04-22/
- https://reuters.com/business/healthcare-pharmaceuticals/struggling-us-healthcare-stocks-endure-rough-2025-draw-some-bargain-hunters-2025-08-07/
- https://reuters.com/world/bristol-myers-must-face-67-billion-lawsuit-over-delayed-cancer-drug-us-judge-2025-12-01/
For informational purposes only; not investment advice.
